- Home
- EDU vs DVA Comparison
EDU vs DVA Comparison
Compare EDU & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDU
- DVA
- Stock Information
- Founded
- EDU 1993
- DVA 1994
- Country
- EDU China
- DVA United States
- Employees
- EDU N/A
- DVA N/A
- Industry
- EDU Other Consumer Services
- DVA Misc Health and Biotechnology Services
- Sector
- EDU Real Estate
- DVA Health Care
- Exchange
- EDU Nasdaq
- DVA Nasdaq
- Market Cap
- EDU 8.5B
- DVA 9.4B
- IPO Year
- EDU 2006
- DVA 1995
- Fundamental
- Price
- EDU $58.05
- DVA $124.80
- Analyst Decision
- EDU Buy
- DVA Hold
- Analyst Count
- EDU 6
- DVA 3
- Target Price
- EDU $57.87
- DVA $151.00
- AVG Volume (30 Days)
- EDU 1.2M
- DVA 654.7K
- Earning Date
- EDU 10-28-2025
- DVA 10-29-2025
- Dividend Yield
- EDU 2.08%
- DVA N/A
- EPS Growth
- EDU N/A
- DVA 5.71
- EPS
- EDU 2.27
- DVA 9.76
- Revenue
- EDU $4,987,826,000.00
- DVA $13,317,965,000.00
- Revenue This Year
- EDU $9.95
- DVA $5.95
- Revenue Next Year
- EDU $9.91
- DVA $3.60
- P/E Ratio
- EDU $25.51
- DVA $12.96
- Revenue Growth
- EDU 7.29
- DVA 5.14
- 52 Week Low
- EDU $40.66
- DVA $122.93
- 52 Week High
- EDU $68.53
- DVA $179.60
- Technical
- Relative Strength Index (RSI)
- EDU 57.79
- DVA 39.30
- Support Level
- EDU $55.00
- DVA $126.57
- Resistance Level
- EDU $59.53
- DVA $130.82
- Average True Range (ATR)
- EDU 2.07
- DVA 2.49
- MACD
- EDU -0.06
- DVA 0.16
- Stochastic Oscillator
- EDU 66.38
- DVA 23.69
About EDU New Oriental Education & Technology Group Inc.
New Oriental Education & Technology is a prominent private education provider in China, offering a wide array of educational services. These include overseas test preparation and consulting services, high school academic tutoring, nonacademic tutoring, and intelligent learning systems and devices. Additionally, the company holds a 57% ownership stake in East Buy, a leading player in the livestreaming e-commerce market.
About DVA DaVita Inc.
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business. Berkshire Hathaway owns about 45% of DaVita.